Cetuximab-Conjugated Magnetic Poly(Lactic-co-Glycolic Acid) Nanoparticles for Dual-Targeted Delivery of Irinotecan in Glioma Treatment

A glioma is the most common malignant primary brain tumor in adults and categorized according to its growth potential aggressiveness. Within gliomas, grade 4 glioblastoma remains one of lethal solid tumors, with a median survival time less than 18 months. By encapsulating CPT-11 oleic acid-coated magnetic nanoparticles (OMNPs) poly(lactic-co-glycolic acid) (PLGA) nanoparticles, we first prepared PLGA@OMNP@CPT-11 this study. After conjugating cetuximab (CET) PLGA@OMNP@CPT-11, spherical PLGA@OMNP@CPT-11-CET 250 nm diameter, 33% drug encapsulation efficiency, 22% loading efficiency were single emulsion/evaporation step. The used for dual-targeted delivery U87 cells by actively targeting overexpressed epidermal factor receptor on surface cells, as well targeting. physicochemical properties characterized detail. CET-mediated promotes intracellular uptake which can release four times more at pH 5 7.4 facilitate endosomes after uptake. nanovehicle PLGA@OMNP-CET cytocompatible hemocompatible. CPT-11, shows highest cytotoxicity toward compared free providing lowest concentration half-maximal cell death (IC50) rate apoptosis. In orthotopic tumor-bearing nude mice xenografts, intravenous injection PLGA@OMNP@ CPT-11-CET followed guidance field provided best treatment efficacy tumor-associated signal intensity from bioluminescence imaging.